June 24, 2009
Sensible Medical Innovation Gets $7 Million to Develop Noninvasive Device to Detect Congestive Heart Failure
Sensible Medical Innovation announced today that it has received a $7 million in capital to develop a noninvasive device to detect congestive heart failure. The funding for this innovation came from two vc firms, Vitalife and Genisis Partners.
Founded in 2007, Sensible Medical Innovation was the brainchild of Amir Ronen, who also serves the company as its CEO.
Currently there is no noninvasive diagnostic procedure to detect congestive heart failure, however, Sensible Medical Innovation has developed an imaging device that will soon replace the need for exploratory surgery to detect congestive heart failure. The device already succeeded in its testing on animals and is now ready for testing on humans. The way this device works is that it uses a uniquely Israeli imaging device that can view and examine internal organs, but the way this technology works is not being revealed by Sensible Medical Innovation. However, this marriage of medical and information technology is a rather attractive innovation and has attracted both the Vitalife and Genesis Partners. Furthermore, should this device come to market, it will replace the need to implant diagnostic devices used by hospitals and cardiologists for the detection of congestive heart failure today.
The Vitalife Fund is a vc firm that is dedicated to companies in the life sciences industry. Some companies in Vitalife’s portfolio include Mediguide, SideLight, Procognia, Florence Medical, TransPharma, Denx Ltd., and others.
Founded in 1996, Genesis Partners is a leading vc firm based in Israel and focuses on early stage companies in the communications and information technology industry. Genesis Partners has over $600 million in four funds, and the vc firm has already invested in over 80 new companies and made 28 successful exits. Genesis also has good standing with Israel’s entrepreneurial community and the global tech industry. Some other companies in Genesis Partners’ portfolio include Advasense, bSolar, Colbar, Lucid, Modu, and others.